Top

Published in:

01-08-2006 | Article

HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden

Authors: E. Bakhtadze, H. Borg, G. Stenström, P. Fernlund, H. J. Arnqvist, A. Ekbom-Schnell, J. Bolinder, J. W. Eriksson, S. Gudbjörnsdottir, L. Nyström, L. C. Groop, G. Sundkvist

Published in: Diabetologia | Issue 8/2006

Abstract

Aims/hypothesis

The World Health Organization considers an aetiological classification of diabetes to be essential. The aim of this study was to evaluate whether HLA-DQB1 genotypes facilitate the classification of diabetes as compared with assessment of islet antibodies by investigating young adult diabetic patients.

Subjects and methods

Blood samples were available at diagnosis for 1,872 (90%) of the 2,077 young adult patients (aged 15–34 years old) over a 5-year period in the nationwide Diabetes Incidence Study in Sweden. Islet antibodies were measured at diagnosis in 1,869 patients, fasting plasma C-peptide (fpC-peptide) after diagnosis in 1,522, while HLA-DQB1 genotypes were determined in 1,743.

Results

Islet antibodies were found in 83% of patients clinically considered to have type 1 diabetes, 23% with type 2 diabetes and 45% with unclassifiable diabetes. After diagnosis, median fpC-peptide concentrations were markedly lower in patients with islet antibodies than in those without (0.24 vs 0.69 nmol/l, p<0.0001). Irrespective of clinical classification, patients with islet antibodies showed increased frequencies of at least one of the risk-associated HLA-DQB1 genotypes compared with patients without. Antibody-negative patients with risk-associated HLA-DQB1 genotypes had significantly lower median fpC-peptide concentrations than those without risk-associated genotypes (0.51 vs 0.74 nmol/l, p=0.0003).

Conclusions/interpretation

Assessment of islet antibodies is necessary for the aetiological classification of diabetic patients. HLA-DQB1 genotyping does not improve the classification in patients with islet antibodies. However, in patients without islet antibodies, HLA-DQB1 genotyping together with C-peptide measurement may be of value in differentiating between idiopathic type 1 diabetes and type 2 diabetes.

Landin-Olsson M, Karlsson FA, Lernmark Å, Sundkvist G; Diabetes Incidence Study in Sweden Group (1992) Islet cell and thyrogastric antibodies in 633 consecutive 15–34 yr-old patients in the Diabetes Incidence Study in Sweden. Diabetes 41:1022–1027PubMedCrossRef

Tuomi T, Carlsson A, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157PubMedCrossRef

Weets I, Siraux V, Daubresse JC et al (2002) Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. J Clin Endocrinol Metab 87:2597–2605PubMedCrossRef

Arnqvist HJ, Littorin B, Nyström L et al (1993) Difficulties in classifying diabetes at presentation in the young adult. Diabet Med 10:606–613PubMedCrossRef

Wroblewski M, Gottsäter A, Lindgärde F, Fernlund P, Sundkvist G (1998) Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40–75 years. Diabetes Care 21:250–255PubMedCrossRef

Turner R, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350:1288–1293PubMedCrossRef

Littorin B, Sundkvist G, Hagopian W et al (1999) Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care 22:409–412PubMedCrossRef

Nerup J, Platz P, Anderson OO et al (1974) HLA antigens and diabetes mellitus. Lancet ii:864–866CrossRef

Todd JA, Bell JI, McDevitt HO (1987) HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329:599–604PubMedCrossRef

10.

Thorsby E, Ronningen KS (1993) Particular HLA-DQ molecules play a dominant role in determining susceptibility or resistance to type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:371–377PubMedCrossRef

11.

Littorin B, Sundkvist G, Scherstén B et al (1996) Patient administrative system as a tool to validate the ascertainment in the diabetes incidence study in Sweden (DISS). Diabetes Res Clin Pract 33:129–133PubMedCrossRef

12.

Ilonen J, Reijonen H, Herva E et al (1996) Rapid HLA-DQB1 genotyping for four alleles in the assessment of risk for IDDM in the Finnish population. The Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 19:795–800PubMedCrossRef

13.

Stenström G, Berger B, Borg H, Fernlund P, Dorman JS, Sundkvist G (2002) HLA-DQ genotypes in classical type 1 diabetes and in latent autoimmune diabetes of the adult. Am J Epidemiol 156:787–796PubMedCrossRef

14.

Landin-Olsson M, Sundkvist G, Lernmark Å (1987) Prolonged incubation in the two-colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30:327–332CrossRef

15.

Borg H, Fernlund P, Sundkvist G (1997) Measurement of antibodies against glutamic acid decarboxylase (GADA): two new ¹²⁵I assays compared with [³⁵S]GAD 65-ligand binding assay. Clin Chem 43:779–785PubMed

16.

Borg H, Fernlund P, Sundkvist G (1997) Protein tyrosine phosphatase IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus. Clin Chem 43:2358–2363PubMed

17.

Gottsäter A, Landin-Olsson M, Fernlund P, Gullberg B, Lernmark Å, Sundkvist G (1992) Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation. A comparison between insulin and C-peptide to measure insulin secretion. Scand J Lab Invest 52:631–639CrossRef

18.

Törn C, Landin-Olsson M, Östman J et al (2000) Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 16:442–447PubMedCrossRef

19.

Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP (2000) Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. J Clin Endocrinol Metab 85:1255–1260PubMedCrossRef

20.

LaGasse JM, Brantley MS, Leech NJ et al (2002) Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 25:505–511PubMedCrossRef

21.

Redondo MJ, Babu S, Zeidler A et al (2006) Specific HLA DQ influence on expression of anti-islet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab 91:1705–1713PubMedCrossRef

22.

Pietropaolo M, Becker DJ, LaPorte RE et al (2002) Progression to insulin-requiring diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high-risk haplotypes. Diabetologia 45:66–76PubMedCrossRef

23.

Sundkvist G, Hagopian WA, Landin-Olsson M et al (1994) Islet cell antibodies (ICA), but not glutamic acid decarboxylase antibodies (GAD65-Ab), are decreased by plasmapheresis in patients with newly diagnosed insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 78:1159–1165PubMedCrossRef

24.

Landin-Olsson M, Arnqvist HJ, Blohmé G et al (1999) Appearance of islet cell autoantibodies after clinical diagnosis of diabetes mellitus. Autoimmunity 29:57–63PubMedCrossRef

25.

Decochez K, Tits J, Coolens JL et al (2000) High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care 23:838–844PubMedCrossRef

26.

Borg H, Arnqvist HJ, Bjork E et al (2003) Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15–34 yrs) in the Diabetes Incidence Study in Sweden (DISS). Diabetologia 46:173–181PubMedCrossRef

27.

Caillat-Zucman S, Garchon H-J, Timsit J et al (1992) Age-dependent HLA genetic heterogeneity of Type 1 insulin-dependent diabetes mellitus. J Clin Invest 90:2242–2250PubMedCrossRef

28.

Tait BD, Harrison LC, Drummond BP, Stewart V, Varney MD, Honeyman MC (1995) HLA antigens and age at diagnosis of insulin-dependent diabetes mellitus. Hum Immunol 42:116–122PubMedCrossRef

29.

Valdes AM, Thomson G, Erlich HA, Noble JA (1999) Association between type 1 diabetes age of onset and HLA among sibling pairs. Diabetes 48:1658–1661PubMedCrossRef

30.

Emery LM, Babu S, Bugawan TL et al (2005) Newborn HLA-DR,DQ genotype screening: age- and ethnicity-specific type 1 diabetes risk estimates. Pediatr Diabetes 6:136–144PubMedCrossRef

31.

Hagopian WA, Sanjeevi CB, Kockum I et al (1995) Glutamate decarboxylase-, insulin- and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest 95:1505–1511PubMedCrossRef

32.

Graham J, Hagopian WA, Kockum I et al (2002) Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 51:1346–1355PubMedCrossRef

33.

Genovese S, Bonfanti R, Bazzigaluppi E et al (1996) Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia 39:1223–1226PubMedCrossRef

34.

Savola K, Bonifacio E, Sabbah E et al (1998) IA-2 antibodies—a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group. Diabetologia 41:424–429PubMedCrossRef

35.

Bottazzo GF, Bosi E, Cull CA et al (2005) IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 48:703–708PubMedCrossRef

36.

Gorus FK, Goubert P, Semakula C et al (1997) IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia 40:95–99PubMedCrossRef

37.

Verge CF, Howard NJ, Rowley MJ et al (1994) Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. Diabetologia 37:1113–1120PubMedCrossRef

38.

Sabbah E, Kulmala P, Veijola R et al (1996) Glutamic acid decarboxylase antibodies in relation to other autoantibodies and genetic risk markers in children with newly diagnosed insulin-dependent diabetes. J Clin Endocrinol Metab 81:2455–2459PubMedCrossRef

39.

Weets I, Van Autreve J, Van der Auwera BJ et al (2001) Male-to-female excess in diabetes diagnosed in early adulthood is not specific for the immune-mediated form nor is it HLA-DQ restricted: possible relation to increased body mass index. Diabetologia 44:40–47PubMedCrossRef

40.

Blohmé G, Nyström L, Arnqvist HJ et al (1992) Male predominance of Type 1 (insulin-dependent) diabetes mellitus in young adults: results from a 5-year prospective nationwide study of the 15–34 year age group in Sweden. Diabetologia 35:56–62PubMedCrossRef

41.

Vandewalle CL, Coeckelberghs MI, Leeuw IH et al (1997) Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Diabetes Care 20:1556–1561PubMedCrossRef

42.

Gale EA, Gillespie KM (2001) Diabetes and gender. Diabetologia 44:3–15PubMedCrossRef

43.

Kyvik KO, Nystrom L, Gorus F et al (2004) The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia 47:377–384PubMedCrossRef

44.

Borg H, Gottsater A, Fernlund P, Sundkvist G (2002) A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 51:1754–1762PubMedCrossRef

45.

Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G (2001) High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 86:3032–3038PubMedCrossRef

46.

Schölin A, Törn C, Nyström L et al (2004) Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in type 1 diabetes. Diabet Med 21:447–455PubMedCrossRef

47.

Schölin A, Björklund L, Borg H et al (2004) Islet antibodies and remaining ß-cell function eight years after diagnosis of autoimmune diabetes in young adults. A prospective follow-up of the nationwide Diabetes Incidence Study in Sweden (DISS). J Intern Med 255:384–391PubMedCrossRef

Title: HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden
Authors: E. Bakhtadze
H. Borg
G. Stenström
P. Fernlund
H. J. Arnqvist
A. Ekbom-Schnell
J. Bolinder
J. W. Eriksson
S. Gudbjörnsdottir
L. Nyström
L. C. Groop
G. Sundkvist
Publication date: 01-08-2006
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 8/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0293-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Subjects and methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 8/2006

IL-1β-induced pro-apoptotic signalling is facilitated by NCAM/FGF receptor signalling and inhibited by the C3d ligand in the INS-1E rat beta cell line

Reductions in caloric intake and early postnatal growth prevent glucose intolerance and obesity associated with low birthweight

Walking performance in people with diabetic neuropathy: benefits and threats

Partial rescue of in vivo insulin signalling in skeletal muscle by impaired insulin clearance in heterozygous carriers of a mutation in the insulin receptor gene

Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids

Signalling mechanisms linking hepatic glucose and lipid metabolism

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials